MetaCap

Tiziana Life Sciences Ltd. (TLSA)

NASDAQ: TLSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.6206-0.055 (-8.14%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TLSA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$79.45M
EPS (TTM)
-$0.21
52-week range
0.55 – 1.90
Day range
0.6119 – 0.70
Volume / Avg
231.24K / 606.04K
Beta
—

52-week range

$0.55$1.90

TLSA stock today

Tiziana Life Sciences (TLSA) closed at $0.6206 on Nov 20, down 8.14% (-$0.055), versus the S&P 500's 3.70% decline. Trading was light, with 231.24K shares changing hands, about 38% of the average daily volume. At this level, TLSA sits near the bottom of its 52-week range of $0.55 to $1.90: 67.3% below the high, set on Dec 2, 2025 and 12.8% above the low.

TLSA is down 58.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 64.3%. Tiziana Life Sciences has posted a net loss over the last twelve months (EPS of -$0.21), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Tiziana Life Sciences

Company profile

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Ivor R. Elrifi Ph.D.
Headquarters
London
Employees
10
IPO year
2018

Financial highlights

Full financials

Tiziana Life Sciences reported a net loss of $11.9 million, compared with a loss of $17.7 million a year earlier. Diluted earnings per share came in at -$0.11.

Tiziana Life Sciences annual revenue, net income and EPS
Fiscal yearFY 2024FY 2023FY 2022FY 2021FY 2020
Revenue—————
Growth—————
Net income$-11.86M$-17.69M$-15.40M$-23.42M$-26.13M
EPS (diluted)$-0.11$-0.17$-0.15$-0.24$-0.16

Analyst forecast

Forecast

Consensus (2 analysts)

none

Avg. price target

$8.09+1203.58%

  • Strong buy 0
  • Buy 2
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $7.08High $9.10

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

TLSA news

All TLSA news

Tiziana Life Sciences peers

Health Care sector
TLSA peer companies
CompanyPrice% ChgMarket capCompare
NKTXNkarta Inc.1.14+1.34%$81.29Mvs TLSA
HURATuHURA Biosciences Inc.1.25-8.09%$82.20Mvs TLSA
OGIOrganigram Global Inc.0.583-7.40%$82.27Mvs TLSA
ANIXAnixa Biosciences Inc.2.44-6.15%$84.82Mvs TLSA
UPBUpstream Bio Inc.1.59-20.50%$87.15Mvs TLSA
EQEquillium Inc.1.06-5.36%$87.26Mvs TLSA
RTSNRetension Pharmaceuticals Inc.10.51-19.22%$87.57Mvs TLSA
CPIXCumberland Pharmaceuticals Inc.5.84-7.30%$87.57Mvs TLSA

Indexes, lists and sector

Tiziana Life Sciences stock FAQ

What is Tiziana Life Sciences's stock price today?

TLSA last traded at $0.6206 as of Nov 20, 4:00 PM EST, down 8.14% on the day. Prices are delayed at least 15 minutes.

Does Tiziana Life Sciences pay a dividend?

No. Tiziana Life Sciences does not currently pay a regular cash dividend.

Who is Tiziana Life Sciences's CEO?

Dr. Ivor R. Elrifi Ph.D. is the chief executive officer of Tiziana Life Sciences Ltd., which has about 10 employees.

Has TLSA ever split its stock?

Yes. The most recent TLSA stock split was a 2499-for-1000 split on Jul 31, 2020, one of 2 splits on record.

What is the TLSA 52-week high?

The 52-week high for TLSA is $1.90 and the 52-week low is $0.55. The stock is currently 67.3% below its high.

Compare TLSA